Phaseline

Targets › NQO1

NQO1 (NAD(P)H dehydrogenase [quinone] 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Dec 2027.

Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species (By similarity). (UniProt, P15559)

Open in Phaseline: the race on NQO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PTC TherapeuticsVatiquinone
Quinone reductase 1 modulator
NQO1Phase 3Friedreich AtaxiaDec 2027

Conditions

Friedreich Ataxia (1)

Modalities

small molecule (1)

Companies

PTC Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.